MICROWAVE-ASSISTED SYNTHESIS OF QUINOXALINES
2061
156.5, 155.3, 154.7, 148.7, 148.6, 148.2, 143.3, 139.9, 136.9, 136.8, 130.9, 125.7, 124.3,
124.2, 123.8, 123.6, 123.5. MS m=z (%): 329 (Mþ, 54), 282 (8), 78 (100).
Phenyl(2,3-di(pyridin-2-yl)quionxalin-6-yl)methanone 3l. Pale yellow
solid; mp (ꢁC): 164–166. IR (t=cmꢂ1): 3078, 2935, 1854, 1613, 1550, 1440, 1284,
1
1059, 977, 764, 692; H NMR (400 MHz, CDCl3): d ¼ 8.59 (s, 1H), 8.40–8.31 (m,
4H), 8.05–8.02 (m, 1H), 7.97–7.80 (m, 5H), 7.67–7.63 (m, 1H), 7.54 (t, J ¼ 6.8 Hz,
2H), 7.29–7.24 (m, 2H); 13C NMR (100 MHz, CDCl3): d ¼ 195.7, 157.0, 156.9,
154.1, 153.6, 148.7, 142.9, 140.1, 138.8, 137.0, 136.8, 136.7, 132.9, 132.5, 130.4,
130.1, 129.9, 128.5, 124.3, 124.2, 123.3, 123.2. MS m=z (%):387 (Mþ ꢂ 1, 84), 105
(54), 77 (100). Anal. calcd. for C25H1N4O: C, 77.30; H, 4.15; N, 14.42. Found: C,
77.72; H, 4.05; N, 14.71.
4a,5,6,7,8,8a-Hexahydro-2,3-di(pyridin-2-yl)quinoxline 3m. White solid;
mp (ꢁC): 188–189. IR (t=cmꢂ1): 3043, 2925, 1585, 1427, 1390, 1178, 1150, 995,
792; 1H NMR (400 MHz, CDCl3): d ¼ 8.46–8.45 (m, 2H), 7.69–7.65 (m, 2H),
7.60–7.58 (m, 2H), 7.27–7.17 (m, 2H), 3.11 (s, 4H), 2.17–1.99 (m, 4H); 13C NMR
(100 MHz, CDCl3): d ¼ 157.1, 151.6, 149.0, 136.2, 124.3, 122.6, 77.2, 31.9, 22.7.
MS m=z (%): 289 (Mþ, 100), 77 (26). Anal. calcd. for C18H18N4: C, 74.46; H,
6.25; N, 19.30. Found: C, 74.72; H, 6.05; N, 19.91.
2,3,6-Trimethylquinoxaline 3n. White solid; mp (ꢁC): 93. IR (t=cmꢂ1):
1
3015, 2925, 1623, 1157, 987, 831, 571, 430; H NMR (400 MHz, CDCl3): d ¼ 7.86
(d, J ¼ 8.0 Hz, 1H), 7.75 (s, 1H), 7.49 (d, J ¼ 8.8 Hz, 1H), 2.71 (s, 6H), 2.56 (s,
3H); 13C NMR (100 MHz, CDCl3): d ¼ 153.3, 152.4, 141.1, 139.5, 139.1, 131.0,
127.8, 127.2, 23.1, 23.0, 21.7. MS m=z (%): 172 (Mþ, 100), 131 (91), 89 (34), 63 (15).
2,3-Dimethyl-6-nitroquinoxaline 3o. Brown solid; mp (ꢁC): 136–137 (lit.[19]
134–135). IR (t=cmꢂ1): 3046, 2957, 2857, 1524, 1401, 1340, 1161, 846, 818, 743, 421;
1H NMR (400 MHz, CDCl3): d ¼ 8.87 (s, 1H), 8.43 (dd, J ¼ 2.8, 8.8 Hz, 1H), 8.10 (d,
J ¼ 9.2 Hz, 1H), 2.78 (s, 6H); 13C NMR (100 MHz, CDCl3): d ¼ 157.2, 156.3, 147.2,
143.7, 139.9, 129.9, 124.9, 122.3, 23.5, 23.3. MS m=z (%): 203 (Mþ, 100), 162 (93),
116 (77), 75 (94).
2,3-Dimethylquinoxaline 3p. White solid; mp (ꢁC): 108 (lit.[20] 104–106). IR
(t=cmꢂ1): 3000, 2914, 1485, 1392, 1319, 1161, 982, 759; 1H NMR (400 MHz, CDCl3):
d ¼ 7.99–7.96 (m, 2H), 7.67–7.64 (m, 2H), 2.72 (s, 6H); 13C NMR (100 MHz,
CDCl3): d ¼ 153.4, 141.1, 128.8, 128.3, 23.2. MS m=z (%): 158 (Mþ, 56), 117 (100),
76 (44), 50 (40).
(2,3-Dimethylquinoxalin-6-yl)(phenyl)methanone 3q. Brown solid; mp
(ꢁC): 124. IR (t=cmꢂ1): 3272, 2997, 2914, 1710, 1641, 1446, 1253, 851, 726, 759;
1H NMR (400 MHz, CDCl3): d ¼ 8.36 (s, 1H), 8.17 (d, J ¼ 8.4 Hz, 1H), 8.09 (d,
J ¼ 8.4 Hz, 1H), 7.87 (d, J ¼ 8.4 Hz, 2H), 7.64–7.60 (m, 1H), 7.53–7.49 (m, 2H),
2.78 (s, 3H), 2.75 (s, 3H); 13C NMR (100 MHz, CDCl3): d ¼ 195.9, 155.7, 154.8,
143.0, 140.0, 137.4, 137.3, 132.6, 131.7, 130.1, 128.8, 128.4, 23.4, 23.2. MS m=z
(%): 262 (Mþ, 44), 185 (85), 105 (100), 77 (82).
7-Bromo-2,3-dimethylpyrido[2,3-b]pyrazine 3r. White solid; mp (ꢁC): 149
(lit.[21] 150). IR (t=cmꢂ1): 3036, 2924, 1864, 1633, 1548, 1442, 1290, 1049, 972, 714;